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Abstract: 
 
 
 
It is often argued that the efficacy of herbal medicines is a result of the combined action of 
multiple constituents that work synergistically or additively. Determining the bioactive 
constituents in these mixtures poses a significant challenge. We have developed an approach to 
address this challenge, synergy-directed fractionation, which combines comprehensive mass 
spectrometry profiling with synergy assays and natural products isolation. The applicability of 
synergy-directed fractionation was demonstrated using the botanical medicine goldenseal 
(Hydrastis canadensis) as a case study. Three synergists from goldenseal were identified, 
sideroxylin (1), 8-desmethyl-sideroxylin (2), and 6-desmethyl-sideroxylin (3). These flavonoids 
synergistically enhance the antimicrobial activity of the alkaloid berberine (also a constituent of 
H. canadensis) against Staphylococcus aureus by inhibition of the NorA multidrug resistance 
pump. The flavonoids possess no inherent antimicrobial activity against S. aureus; therefore, 
they could have been missed using traditional bioactivity-directed fractionation. The flavonoid 
synergists are present at higher concentration in extracts from H. canadensis leaves, while the 
antimicrobial alkaloid berberine is present at higher levels in H. canadensis roots. Thus, it may 
be possible to produce an extract with optimal activity against S. aureus using a combination of 
goldenseal roots and leaves. 
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Article:  
 
Investigators who study botanical medicines face a formidable challenge. The effects of such 
preparations can result from the interaction of an array of chemically diverse components, whose 
identity and concentration may vary from one preparation to the next. Proponents of the 
medicinal use of botanicals often argue that their components interact synergistically, such that 
the combined effect is greater than the sum of the parts. Indeed, there are many examples in the 
literature whereby constituents are more effective in the phytochemical matrix than when 
isolated.(1, 2) However, the specific components responsible for these effects, and the 
fundamental mechanisms by which they interact, are rarely known. Methods are needed to 
unravel the complexity of botanical medicines and identify their key bioactive constituents. Such 
information would in turn enable better quality control and more meaningful and reproducible 
clinical trials. 
 
A common approach for studying complex plant preparations is bioactivity-guided fractionation. 
With this technique, extracts are screened in pursuit of those that contain biologically active 
compounds. The active extracts are then partitioned and purified, with the ultimate goal of 
identifying single active compounds. A limitation of bioactivity-guided fractionation for 
studying botanical medicines is that it may not facilitate the identification of synergists. One type 
of synergy, potentiation, occurs when a compound possesses no activity on its own, but enhances 
the activity of another active compound.(3) It is possible with bioactivity-guided fractionation 
for potentiators to end up in inactive fractions throughout the isolation process, and thereby to be 
overlooked. With the studies presented here, we sought to develop a new method, synergy-
directed fractionation, which would facilitate identification of an array of biologically active 
compounds, including synergists, in a complex botanical medicine. 
 
The botanical medicine goldenseal, Hydrastis canadensis L. (Ranunculaceae), is presented as a 
case study for the development of the methods presented herein. A recent survey ranked 
goldenseal among the 20 most popular herbal supplements used worldwide,(4) and it is reported 
as the sixth most commonly used herbal preparation by children under 18 years of 
age.(5) Goldenseal is recommended as a treatment for a number of ailments, including viral and 
bacterial infections and as an antidiarrheal.(6) This use dates back to traditional application by 
Native Americans; the Cherokee employed the plant topically for eye and skin disease, and it 
was used by the Iroquois for gastrointestinal issues.(7) There is some justification in the 
scientific literature for the effectiveness of goldenseal and its constituents. Crude goldenseal 
root(8-12) and leaf(10) extracts, and their most abundant alkaloid berberine,(13-15) have been 
shown to possess antimicrobial activity in vitro. Berberine has also demonstrated efficacy in vivo 
against severe diarrhea(16) and eye infections caused by Chlamydia trachomatis.(17) 
 
While the antibacterial activity of goldenseal is generally attributed to alkaloids, several 
investigators have suggested a role for additional compounds that synergistically or additively 
enhance the effectiveness of the alkaloids.(8, 9, 18) Most recently, we reported that extracts from 
the leaves of goldenseal contain synergists that increase the antimicrobial activity of the alkaloid 
berberine against Staphylococcus aureus.(19) Berberine alone has only weak antimicrobial 
activity (MIC ∼150 μg/mL).(20) This low activity can be attributed, at least in part, to berberine 
being a substrate for bacterial multidrug resistant (MDR) efflux pumps, which function to 
extrude the compound from bacterial cells, rendering it inactive at low concentrations.(20) We 
have determined that goldenseal leaf extracts contain unidentified constituents that appear to act 
as inhibitors of NorA, the major chromosomal multidrug resistance efflux pump expressed by S. 
aureus.(19) These findings are significant given that a major mechanism by which bacteria 
become resistant to treatment is by the overexpression of efflux pumps.(21)Thus, it may be 
possible, using extracts that contain both efflux pump inhibitors and antimicrobial agents, to 
achieve efficacy against drug-resistant bacteria and to limit the development of resistance. A 
major goal of these studies was to employ synergy-directed fractionation to identify the 
compounds in H. canadensis leaf extracts that synergize the antimicrobial activity of berberine. 
In so doing, we sought to demonstrate the applicability of synergy-directed fractionation as a 
method to study botanical medicines. Additional goals were to investigate efflux pump inhibition 
as the likely mode of action for synergists from H. canadensis and to compare the abundance of 
active compounds in extracts from the roots and leaves of this plant. 
 
RESULTS AND DISCUSSION 
 
The approach for synergy-directed fractionation developed as a result of these studies is outlined 
in Figure 1. Crude extracts are subjected to synergy testing to identify those likely to contain 
synergists. Active extracts are fractionated, and each fraction is profiled using liquid 
chromatography–mass spectrometry (LC-MS) and again subjected to a synergy assay. LC-MS 
profiles are compared to bioactivity data, and statistical correlations are used to identify potential 
bioactive compounds (which could include both synergists and those responsible for direct 
activity). The process of fractionation, synergy testing, and analysis with LC-MS is repeated 
iteratively until sufficient pure material is obtained for structure elucidation with NMR and MS. 
 
The synergy-directed fractionation approach is perhaps best illustrated by example. In the 
following section, we demonstrate its application to identify synergists from the botanical 
medicine goldenseal (H. canadensis). Leaf material was chosen for this study because previous 
studies showed greater synergistic antimicrobial activity of goldenseal leaf extracts than 
goldenseal root extracts.(19) The first step in the process of identifying the compounds 
responsible for this effect was to select an appropriate method to assay synergy. The 
checkerboard assay,(22) which has been widely applied to study antimicrobial synergists, was 
chosen. To conduct the checkerboard assay, a crude H. canadensis leaf extract was tested at a 
range of concentrations in combination with the known antimicrobial agent berberine (also a 
component of H. canadensis). Minimum inhibitory concentrations (MIC) were measured for 
each combination of berberine/goldenseal extract concentrations, and an isobologram was 
plotted (Figure 2). Wagner has presented an excellent review of the use and interpretation of 
isobolograms for evaluation of synergy among phytochemical compounds.(2) Briefly, an 
isobologram is a plot where each x,y data pair represents a combination of concentrations at 
which a desired activity is obtained (i.e., growth of bacteria is completely inhibited). The shape 
of the isobologram is indicative of either synergistic, additive, or antagonistic interactions among 
the compounds or extracts tested. As a quantitative measure of synergy, fractional inhibitory 
concentrations (FIC) can also be calculated using the same data on which the isobologram is 
based, as described elsewhere.(19) An FIC cutoff of <0.5 is usually applied to indicate 
synergy,(23) while an antagonistic effect is characterized by FIC >4, and FIC values between 0.5 
and 4 indicate no interaction.(22) In this study, the crude H. canadensis extract demonstrated 
synergism when combined with berberine, as indicated by the convex shape of the isobologram 
(Figure 2) and the FIC value of 0.19 (Table 1). 
 
 
 
 
Figure 1. Synergy-directed fractionation. Synergy testing is used to identify extracts and 
fractions likely to contain combinations of compounds that work together. These extracts are 
then fractionated, and LC-MS profiles are compared to bioassay data to identify potential 
bioactive compounds. The process is repeated iteratively as necessary to obtain pure compounds 
(synergists), the structures of which are elucidated using NMR and other spectroscopic 
techniques. 
 
Once synergy had been demonstrated for the crude H. canadensis extract, the next step was to 
identify the compounds responsible for this activity. Toward this goal, the extract was 
fractionated (see Figure S1 provided as Supporting Information), and the activity of each fraction 
in combination with berberine was evaluated. Because of limited time and materials, rather than 
construct a full isobologram, the activity of each fraction was measured at a single concentration 
(75 μg/mL) in combination with a range of concentrations of berberine. The MIC of berberine in 
the presence of the fraction was then compared to the MIC of berberine alone, and fractions were 
deemed “active” if they enhanced the activity of the berberine (decreased its MIC). Note that this 
activity does not necessarily imply synergy; a fraction could enhance the activity of berberine 
due to either potentiation or an additive antimicrobial effect. Several of the fractions collected 
from the first-stage fractionation did, indeed, decrease the MIC of berberine (Figure3A). The 
most active of these was fraction 4, which decreased the MIC of berberine 16-fold, from 75 
μg/mL (berberine alone) to 4.7 μg/mL (berberine in combination with fraction 4). 
 
 
 
Figure 2. Isobolograms for berberine, the tannin-free Hydrastis canadensis extract (after liquid–
liquid extraction, see Supporting Information, Figure S1), the most active fraction from the first 
stage of the separation (fraction 4), and the most active fraction from the second stage of the 
separation (subfraction 2). All were tested in combination with berberine. The crude extract and 
its two fractions synergistically enhanced the antimicrobial activity of berberine, as demonstrated 
by the convex shape of the isobolograms, and the FIC values are reported in Table 1. 
 
 
 
A limitation of the simplified approach employed for screening fractions (constant concentration 
of fraction in combination with a range of concentrations of berberine) is that it does not enable 
additive effects to be distinguished from synergistic effects. Thus, the observed activity of 
fraction 4 was tested further with an in-depth synergy assay. A checkerboard assay identical to 
that employed for the crude extract was conducted using a range of combinations of fraction 4 
with berberine. The resulting isobologram (Figure 2) and the FIC value of 0.13 (Table 1) were 
indicative of synergy. 
 
Once it had been determined that fraction 4 did, indeed, contain synergist(s), LC-MS profiles 
were compared to the bioactivity data (Figure 3) to determine whether activity could be 
attributed to specific known or unknown compounds. LC-MS analysis revealed the presence of 
several ions that were not known constituents of H. canadensis in fraction 4. These ions were 
identified initially based on their m/z values (M – H– at 311 and 297). NMR analysis of pure 
isolated compounds eventually enabled their structures to be elucidated as a group of three 
flavonoids (1, 2, and 3), as described below. 
 
It was possible, using LC-MS, to verify that the activity of fraction 4 was not due to the presence 
of the three major known alkaloids in H. canadensis, berberine (4), hydrastine, and canadine. 
From Figure 3C, it is apparent that fractions 9, 10, and 11 contained the highest levels of 
berberine. The weak activity of these fractions (2-fold decrease in MIC) was attributed to this 
compound, and they were not investigated further. Hydrastine and canadine were present at 
higher concentrations in fraction 3 than in fraction 4, but fraction 4 was significantly more 
active. This suggested that other compounds were responsible for the activity of fraction 4, a 
finding that was not surprising given that hydrastine and canadine have been shown to be 
inactive against S. aureus, both alone and in combination with berberine.(19) 
 
Visual inspection of the data in Figure 3 revealed separate correlations with the presence of 
compounds at m/z 297 and 311. The strength of this correlation was evaluated jointly using a 
statistical method. A multiple correlation analysis was conducted to examine the extent of linear 
association between peak areas of ions 297 and 311 and the MIC of the fractions obtained from 
the first-stage separation. A moderate correlation was observed (R = 0.77, p = 0.02), which 
suggests that the joint presence of ions 297 and 311 explains approximately 60% (0.772), but 
does not completely explain the activities observed for the fractions. Presumably, other 
compounds that play a role in the overall activity of the crude extract are also present. Indeed, 
visual inspection of the data could also have led to this conclusion, given that fractions 5 and 6 
demonstrated pronounced activity (8-fold decrease in MIC of berberine) even without significant 
levels of berberine or of the ions with m/z 297 and 311. 
 
 
 
Figure 3. Panel A shows minimum inhibitory concentration (MIC) of starting material (sm), 
berberine alone, and berberine in combination with 11 fractions (each at a fixed concentration of 
75 μg/mL) from the first stage of separation (flash chromatography over silica gel with 
CHCl3/MeOH gradient) of the Hydrastis candensis leaf extract. The MIC of berberine (75 
μg/mL) was reduced significantly by combining with the starting material and with several of the 
fractions, with the most active fraction being fraction 4. Panels B and C show the distribution of 
flavonoids (measured with negative-ion LC-MS) and alkaloids (measured with positive-ion LC-
MS), respectively, in the fractions. Fraction 4 contains the highest levels of the three flavonoids. 
There is a moderate multiple correlation between MIC and flavonoid peak area (R = 0.77, p = 
0.016). 
 
Fraction 4 was subjected to a second stage of separation using flash chromatography with a 
hexane/ethyl acetate gradient (see fractionation scheme, Supporting Information Figure S1). 
Mass spectrometry profiles were compared to MIC data (Figure 4), and again the compounds 
with m/z 297 and 311 were present at highest concentration in the most active fraction 
(subfraction 2). Subfraction 2 was also subjected to the synergy assay (Figure 2), and an even 
more pronounced synergistic enhancement of the activity of berberine was observed (FIC = 
0.03). The second stage of purification yielded multiple active fractions (Figure 4), which 
explains the weak multiple correlation observed between MIC and peak area of compounds 
withm/z 297 and 311 for the second stage of separation (R = 0.55, p = 0.37). This weak 
correlation implies that the compounds with m/z 297 and 311 do not fully account for the activity 
of fraction 4 and that, again, additional active compounds were present in this fraction. 
 
 
 
Figure 4. Comparison between MIC (A) and distribution of flavonoids (B) and alkaloids (C) 
after the second stage of the separation (flash chromatography over silica gel with hexane/EtOAc 
gradient) of the Hydrastis canadensis leaf extract. Subfraction 2 contained the highest levels of 
the three flavonoids and was one of the most active fractions. Note, however, that other 
compounds appear to play a role in the activity of the starting material (sm); several fractions 
with little to no flavonoid content have activity on the same order as subfraction 2. The presence 
of additional active compounds would also explain the weak multiple correlation between 
activity and flavonoid content after this second stage of separation (R = 0.55, p = 0.37). 
 
Two rounds of preparative HPLC starting with subfraction 2 ultimately led to the isolation of the 
flavonoids sideroxylin (1), 6-desmethyl-sideroxylin (2), and 6-desmethyl-sideroxylin (3). These 
flavonoids were the same compounds observed in the LC-MS spectra at m/z 311 (sideroxylin) 
and 297 (isomeric 8-desmethyl-sideroxylin and 6-desmethyl-sideroxylin). The flavonoids have 
been reported previously as constituents of Eucalyptus spp. (1 and 2)(24-26) and Dracaena 
cochinchinensis (3, referred to in the reference by the name 4′,5-dihydroxy-7-methoxy-8-
methylflavone).(27) Ours is the first publication to report these flavonoids as constituents of H. 
canadensis.(28) Other flavonoids have, however, been identified in H. canadensis,(9) and, as 
previously mentioned, it is well known that the plant contains the alkaloid berberine (4). Both 1H 
and 13C NMR chemical shift data (Supporting Information, S2) were in excellent agreement with 
those reported for the flavonoids,(24-27) and high-resolution mass spectrometry measurements 
confirmed the molecular formulas of C18H16O5 for sideroxylin and C17H14O5 for the isomers 8-
desmethyl-sideroxylin and 6-desmethyl-sideroxylin. 
 
 
 
Although the crude extract and early stage fractions were quite soluble in the antimicrobial assay 
medium (Müeller-Hinton broth with 2% DMSO), the isolated flavonoids demonstrated very poor 
solubility (<13 μg/mL) in this same medium. As such, it was not possible to observe an influence 
of the pure flavonoids on the MIC of berberine against wild-type S. aureus. However, activity 
was observed for 8-desmethyl-sideroxylin against a NorA efflux pump overexpressing strain ofS. 
aureus (S. aureus K2378, norA++, Table 2), which is more sensitive to inhibitors. Note that 
although the reported assay concentration of 8-desmethyl-sideroxylin was 75 μg/mL (Table 2), 
the actual concentration was likely much lower, due to the aforementioned poor flavonoid 
solubility. The flavonoid demonstrated no antimicrobial activity alone (MIC >300 μg/mL) 
against the norA++S. aureus, but decreased the MIC of berberine 2-fold. Thus, it can be said that 
8-desmethyl-sideroxylin (2) synergistically enhances, or potentiates, the antimicrobial activity of 
berberine against norA++S. aureus. 
 
 
 
Previous literature has shown flavonoids to act as efflux pump inhibitors,(20, 29, 30) and our 
group has demonstrated efflux pump inhibitory activity for goldenseal leaf extracts.(19) Thus, 
we hypothesized efflux pump inhibition as a likely mode of action for the H. 
canadensis flavonoids. To test this hypothesis, the activity of each of the three individual 
flavonoids was evaluated with an ethidium bromide efflux assay (Figure 5). Ethidium bromide is 
a substrate of the S. aureusefflux pump NorA and fluoresces strongly (due to intercalation with 
DNA) inside bacterial cells.(20) With the ethidium bromide efflux assay, cells are loaded with 
ethidium bromide and fluorescence is monitored over time. A decrease in fluorescence indicates 
efflux of ethidium bromide from the cells, and in the presence of an efflux pump inhibitor, 
fluorescence should decrease more slowly. The ethidium bromide efflux assay has the 
advantages of being more sensitive than the checkerboard synergy assay and also having a 
greater tolerance for DMSO (10% DMSO was used in this assay, as compared to 2% DMSO in 
the checkerboard assays). These features enabled the solubility problems with the pure 
flavonoids to be circumvented when using the efflux assay. 
 
Figure 5A shows the results of the ethidium bromide efflux assay with wild-type S. 
aureus(NCTC 8325-4). The positive control, carbonyl cyanide m-chlorophenylhydrazone 
(CCCP), and compounds 1, 2, and 3 inhibited efflux of ethidium bromide. Significant differences 
between vehicle control (10% DMSO) and treatment with sideroxylin (1) (p = 0.02), 8-
desmethyl-sideroxylin (2) (p = 0.0002), 6-desmethyl-sideroxylin (3) (p = 0.002), and CCCP (p = 
0.0002) were observed at t = 300 s. When the same experiment was repeated using 
the norA deletion mutant S. aureus (K1758), neither CCCP nor any of the flavonoids 
significantly inhibited efflux of ethidium bromide (Figure 5B). The results demonstrate that all 
three flavonoids from S. aureusinhibit the NorA efflux pump of S. aureus. 
 
Although all three flavonoids demonstrated some efflux pump inhibitory activity, they differed 
in potency (Figure 5A). Sideroxylin (1), the dimethyl analogue, was a less effective inhibitor 
than either of the monomethyl analogues, 8-desmethyl-sideroxylin (2) and 6-desmethyl-
sideroxylin (3). It appears that substitution on both the 6 and 8 positions decreases efflux pump 
inhibitory activity. 
 
 
 
Figure 5. The three flavonoids from Hydrastis canadensis inhibit the NorA efflux pump of 
Staphylococcus aureus. Decrease in fluorescence over time is due to efflux of ethidium bromide, 
which is blocked by the positive control (CCCP) and all three flavonoids, sideroxylin (1), 8-
desmethyl-sideroxylin (2), and 6-desmethyl-sideroxylin (3). Sideoxylin is the least active of the 
three flavonoids. The effect is observed with wild-type Staphylococcus aureus (NCTC8325-4) 
(A) but not a NorA deletion mutant (K1758) (B). All of the flavonoids and controls were tested 
at a final concentration of 100 μM in Müeller-Hinton broth containing 10% DMSO (vehicle). 
Each point is an average percent fluorescence from three independent measurements, with error 
bars equal to ±standard error (SE). 
 
A relevant question to the quality control of dietary supplements from H. canadensis aerial 
portions is whether the flavonoids and alkaloids are present at detectable levels in such 
preparations. To address this question, ethanolic extracts were analyzed that had been prepared 
using a method based on that employed in the manufacture of dietary supplements.(31) Both 
flavonoids and alkaloids were detected in the ethanolic extracts. Retention times and CID 
fragmentation patterns for these compounds (see Supporting Information, Table S2) matched 
those of standards. In agreement with previous literature, the alkaloids were present at higher 
levels in extracts prepared from goldenseal roots than leaves.(18) Conversely, the flavonoids 
were detected only at very low levels in the root/rhizome extracts, but at much higher levels in 
the leaf extracts (Table 3). Goldenseal leaf extracts contained an average of 1.9 ± 0.4 mM 8-
desmethyl-sideroxylin/6-desmethyl-sideroxylin (quantified as a mixture) and 73.3 ± 0.9 μM 
sideroxylin. Levels in the root extracts were more than 50 times lower. Notably, the same leaf 
extracts for which data are presented in Table 3 have been shown previously to have efflux pump 
inhibitory activity,(19) which is likely attributable, at least in part, to the presence of flavonoids 
1, 2, and 3. 
 
 
 
The finding that goldenseal leaf extracts have higher levels of synergists while root extracts 
contain higher levels of alkaloids suggests the potential benefit of using a mixture of root and 
leaf material in the production of dietary supplements from goldenseal. Further studies would, 
however, be needed to evaluate the safety and efficacy of goldenseal leaf extracts in vivo. If 
goldenseal leaf material was shown to be efficacious, this could add value to cultivated 
goldenseal crops. In addition, the use of goldenseal leaf material has the added advantage of 
reducing impact on wild goldenseal populations. Goldenseal leaves can be harvested in the fall, 
after the berries have dropped, without killing the plants. Sustainable production of goldenseal 
would be particularly desirable given that it is listed as threatened by CITES in much of its 
native habitat.(32) 
 
In terms of the broader relevance of this study, it has been shown that synergy-directed 
fractionation can be employed to identify both compounds with direct antimicrobial activity 
(berberine) and efflux pump inhibitors that synergistically enhance berberine’s activity (the three 
flavonoids) from a complex botanical extract. The results highlight three important elements that 
distinguish synergy-directed fractionation from bioactivity-guided fractionation. First, the 
application of synergy testing to the crude extract made it possible to determine that it contained 
synergists even prior to fractionation. Second, integration of synergy testing with the 
fractionation process allowed synergists to be tracked as they were purified. This process 
ultimately facilitated the isolation of synergists that possess no inherent antimicrobial activity, 
compounds that may have been missed in inactive fractions with traditional bioactivity-guided 
fractionation. Third, comparison of LC-MS data and biological activity data after each stage of 
separation allowed potential active compounds to be identified and tracked throughout the 
isolation process. This establishes an important linkage between biological activity of the crude 
extract and the presence of specific active compounds. In the example presented here, it was 
possible based on LC-MS profiles to identify ions corresponding to the active flavonoids even 
after only one stage of separation. Importantly, it was not necessary to have prior knowledge of 
the identities of the compounds detected in the active fractions to correlate their presence with 
biological activity. These compounds were initially identified solely on the basis of characteristic 
m/z values, and it was only after their likely role in the biological activity of the extract had been 
established that they were isolated and their identities determined via NMR. 
 
Visual inspection and statistical analyses of the data after the first and second stages of 
separation suggest the presence of multiple active compounds, including some that have not yet 
been identified. By no means does this finding negate the importance of the flavonoids and 
alkaloids in the activity of H. canadensis. Rather, the results suggest that the antimicrobial 
activity of the crude H. canadensis extract is due to multiple compounds, including antimicrobial 
alkaloids, flavonoids that synergistically enhance the antimicrobial activity of the alkaloids, and 
several additional compounds whose identities and modes of action have yet to be determined. 
This finding is consistent with the claims often made for botanical medicines: that their activity 
results from the combined (and perhaps synergistic) action of an array of chemically diverse 
constituents. 
 
EXPERIMENTAL SECTION 
 
General Experimental Procedures 
 
NMR spectra were acquired with a JEOL ECA-500 spectrometer (500 MHz for 1H and 125 MHz 
for 13C) using DMSO-d6. LC-MS measurements were made using an LCQ Advantage (Thermo) 
coupled to an Agilent HP1100 HPLC with a Prevail C18 column (3 μm; 110 Å, 50 × 2.1 mm). 
HRESIMS data were acquired using an LTQ-Orbitrap (Thermo). Flash chromatography 
separations were accomplished using an automated CombiFlash RF system (Teledyne-Isco). 
HPLC separations were performed on a Varian HPLC system (ProStar 210 pumps, ProStar 710 
fraction collector, ProStar 335 photodiode array detector) with Galaxie Chromatography 
Workstation software (version 1.9.3.2). Preparative-scale HPLC separations employed a C-18 
YMC-Pack ODS-A column (5 μm, 120 Å; 250 × 20 mm, Waters) or a Luna PFP(2) column 
(pentafluorophenyl propyl, 5 μm, 100 Å; 250 × 21.2 mm, Phenomenex). Analytical-scale HPLC 
separations were accomplished with YMC ODS-A (5 μm, 120 Å; 150 × 4.6 mm, Waters) and 
Luna PFP(2) (5 μm, 100 Å; 150 × 4.6 mm, Phenomenex) columns. For antimicrobial assays, 
OD600 was read using a POLARstar Optima microplate reader (BMG Labtech, Inc.). 
Fluorescence was monitored in efflux assays using a Spex FluoroMax-2 spectrofluorometer 
(Instruments S. A., Inc.). Müeller-Hinton broth, carbonyl cyanide m-chlorophenylhydrazone, 
berberine (4) (purity >98% by HPLC), (1R,9S)-(−)-β-hydrastine (purity >98% by HPLC), and 
reserpine (purity >98% by TLC) were purchased from Sigma Aldrich, and canadine 
(tetrahydroberberine, purity >98% by HPLC, stereochemistry unconfirmed) was obtained from 
Chromadex. Other reagents were purchased from Fisher Chemical, except EtOH (95%) and 
HPLC-grade MeOH, which were obtained from Pharmco-AAPER. Nanopure water was 
prepared with a Nanodiamond water purification system (Barnstead). 
 
Plant Material 
 
Individual goldenseal (Hydrastis canadensis) plants and bulk leaf material were collected in July 
2010 from William Burch in Hendersonville, North Carolina (NC, N 35°24.277′, W 082°20.993′, 
702.4 m elevation). The plants were cultivated in their native environment, a hardwood forest 
understory, and were at least 5 years old at time of harvest. A voucher specimen was deposited at 
the Herbarium of the University of North Carolina at Chapel Hill (NCU583414) and 
authenticated by Dr. Alan S. Weakly. Samples were air-dried at 37 °C before extraction. This 
temperature was chosen because it was sufficient to dry plant material without causing 
discoloration of the leaves. 
 
Extraction 
 
Ethanolic H. canadensis extracts (50:50 EtOH/H2O) were prepared via a procedure used for the 
preparation of botanical dietary supplements, as described previously.(19) Extracts were 
prepared separately for the root and leaf material from five individual goldenseal plants (for a 
total of 10 extracts, five leaf and five root). An additional larger scale extraction (2.3 kg of leaf 
material) was performed to facilitate isolation. Leaves were homogenized and percolated in 
MeOH overnight, and the MeOH extract was concentrated in vacuo and subjected to liquid–
liquid extraction, as described previously.(33) Briefly, the extract was defatted by partitioning 
between hexane and 10% aqueous MeOH (1:1). The dried aqueous MeOH fraction was 
partitioned further between 4:1:5 CHCl3/MeOH/H2O, and the organic extract was washed with 
1% saline solution to remove hydrosoluble tannins.(34) 
 
Isolation 
 
The isolation scheme is provided as Supporting Information (Figure S1). The first stage of 
normal-phase flash chromatography (330 g silica gel column) was conducted at a 60 mL/min 
flow rate with a 110 min hexane/CHCl3/MeOH gradient. The most active fraction from the first 
stage separation (fraction 4) was subjected to a second stage of normal-phase flash 
chromatography (120 g silica gel column), which employed an 85 mL/min flow rate and a 50 
min hexane/EtOAc/MeOH gradient. The most active fraction from the second-stage separation 
(subfraction 2) was purified using reversed-phase preparative HPLC with a YMC ODS-A 
column at a 8.0 mL/min flow rate. A MeOH/H2O gradient was employed, which progressed 
linearly from 70:30 to 85:15 over 60 min. Compound 1 eluted at 44.85 min (22.2 mg, 98.6% 
purity, 0.00096% yield), and compounds 2 and 3 eluted as a mixture (53.4 mg) between 36.8 and 
37.3 min. The mixture of 2 and 3 was subjected to an additional stage of preparative HPLC using 
a Luna PFP(2) (pentafluorophenyl propyl) stationary phase with a 21.2 mL/min flow rate. An 
CH3CN/H2O gradient was used, initiating at 45:55 (isocratic for 12 min), increasing linearly to 
58:42 from 12.1 to 15.0 min, and from 58:42 to 60:40 from 15.1 to 20.0 min. Compound 2 eluted 
at 17.4 min (14.8 mg, 99% purity, 0.00064% yield), and compound 3 eluted at 15.21 min (2.40 
mg, 98.9% purity, 0.0001% yield). 
 
Sideroxylin (1): 
 
white solid; HRESIMS m/z 311.0922 [M – H–] (calcd for C18H15O5–, 311.0925); 1H NMR (500 
MHz DMSO-d6) and 13C NMR (125 MHz DMSO-d6) chemical shifts were in agreement with 
literature values(24-26) and are provided as Supporting Information (Table S1 and Figure S2). 
 
8-Desmethyl-sideroxylin (2): 
 
white solid; HRESIMS m/z 297.0765 [M – H–] (calcd for C17H13O5–, 297.0768); 1H NMR (500 
MHz DMSO-d6) and 13C NMR (125 MHz DMSO-d6) were in agreement with literature 
values,(24-26) as indicated by chemical shift data (Table S1) and NMR spectra (Figure S2) 
provided as Supporting Information. 
 
6-Desmethyl-sideroxylin (3): 
 
white solid; HRESIMS m/z 297.0761 [M – H–] (calcd for C17H13O5–, 297.0768). 1H NMR (500 
MHz DMSO-d6) and 13C NMR (125 MHz DMSO-d6)(7) data were in agreement with 
literature(27) and are provided for reference as Supporting Information (Table S1 and Figure 
S2). 
 
LC-MS 
 
Alkaloids and flavonoids were quantified and identified using LC-MS with an ion trap mass 
spectrometer. Reversed-phase HPLC was used for the separation with a Prevail C18 column and 
a gradient employing 1% aqueous acetic acid in acetonitrile. The gradient was as follows (ratios 
represent CH3CN/H2O): 0 to 5 min, 0:100 to 32:68; 5.1 to 20 min, 32:68 to 100:0; 20 to 25 min, 
isocratic 100:0; 25 to 25.10 min, 100:0 to 0:100. Extracts were analyzed both in the positive-ion 
mode (for detection and quantification of alkaloids) and the negative-ion mode (for detection and 
quantification of flavonoids). Standards were analyzed over a concentration range of 7.8 × 10–
7 to 1.0 × 10–4 M (flavonoids) and 5.0 × 10–7 to 1.0 × 10–4 M (alkaloids). Calibration curves were 
plotted as the area of the relevant selected ion trace (as detected by the LC-MS) versus 
concentration. Extracts were diluted so that constituents fell within the linear range of the 
calibration curves. The alkaloids berberine, hydrastine, and canadine were identified by 
comparison of retention time, m/z, and CID fragmentation patterns with those of commercial 
standards (see Table S2 provided as Supporting Information), as described previously.(19) The 
flavonoids were identified in the same fashion using compounds 1, 2, and 3, isolated as part of 
this study, as standards. 
 
Antimicrobial Assays 
 
Two strains of S. aureus were employed, wild-type (NCTC 8325-4)(35) and NorA 
overexpressing (K2378, norA++).(36) Minimum inhibitory concentration was evaluated 
according to Clinical Laboratory Standards Institute guidelines.(37) A single colony inoculum 
of S. aureuswas grown to log phase in Müeller-Hinton broth and was adjusted to a final assay 
dilution of 1.0 × 105 cfu/mL based on absorbance at 600 nm (OD600). The negative control 
consisted of 2% DMSO in broth (vehicle), and the known efflux pump inhibitor 
reserpine(38) served as the positive control. Triplicate wells were prepared with all treatments 
and controls. Additional wells were included containing the samples without bacteria, for the 
purpose of background subtraction. OD600 was read after incubation for 20 h at 37 °C. MIC was 
defined as the concentration at which no statistically significant difference was observed (via 
ANOVA) between the negative control and treated samples. 
 
Synergy Testing 
 
Broth microdilution antimicrobial checkerboard assays(19, 22) were performed to evaluate 
synergy for the crude extracts. Extracts were tested in combination with berberine over a 
concentration range of 5 to 300 μg/mL. The antibiotic norfloxacin (positive control) 
demonstrated an MIC value of 2 μg/mL, consistent with the literature.(39) The vehicle control 
consisted of 2% DMSO in broth. To evaluate synergistic interactions, isobolograms were plotted 
and FIC indices calculated, as described previously.(19) After each round of fractionation, a 
simplified version of the synergy assay was used to enable rapid screening of the large number of 
fractions generated. This involved testing berberine at a range of concentrations (5 to 300 
μg/mL) in combination with a constant concentration of each of the extract fractions (75 μg/mL). 
The known efflux pump inhibitor reserpine,(38) also at 75 μg/mL, was employed as a positive 
control for these experiments. Fractions were deemed active if they enhanced the activity of 
berberine (reducing its MIC against S. aureus by at least 2-fold) and were advanced to the next 
stage of separation. Using the simplified synergy assay, it is not possible to distinguish 
synergistic effects from additive effects, so the most active fractions were also subjected to the 
synergy checkerboard assay as described for the crude extracts. 
 
Efflux Pump Inhibition Assay 
 
The efflux pump inhibition assay was conducted using a previously published method.(19) Wild-
type S. aureus (NCTC 8325-4)(35) and an isogenic NorA deletion mutant (K1758 norA–
)(40)were grown to OD600 = 0.74 in Müeller-Hinton broth. Ethidium bromide (25 μM) and 
carbonyl cyanide m-chlorophenylhydrazone (100 μM) were added, and the bacteria were 
incubated at 20 °C with agitation (300 rpm) for 20 min. This solution was diluted to OD600 = 
0.40 with broth containing ethidium bromide and CCCP at 25 and 100 μM, respectively. 
Aliquots (1 mL) of this solution were centrifuged at 20 °C for 5 min at 13000g in a Spectrafuge 
24D centrifuge (Labnet). The pellets were stored on ice for <1 h. Prior to measurement, the 
pellets were thawed for 5 min and 1 mL of fresh broth containing DMSO (10% final assay 
concentration) and treatments (CCCP or flavonoid) was added. Fluorescence of these solutions 
was measured every second for 300 s with λex = 530 nm, λemiss = 600 nm, and slit widths of 5 
mm. 
 
Statistics 
 
Statistical significance of means versus control was evaluated using two-factor ANOVA with p < 
0.05 considered significant. Multiple (canonical) correlations were computed to assess the degree 
of association of MIC jointly with the peak area of several ions (flavonoid 1, m/z 311, and the 
flavonoid 2/3 mixture, m/z 297). The peak areas appeared to be non-normally distributed, and 
sample sizes were small, so p-values for assessing the statistical significance of the multiple 
correlations were calculated using permutation tests. 
 
SUPPORTING INFORMATION 
 
13C and 1 H NMR data, a fractionation scheme, LC-MS fragmentation data, and retention times 
for alkaloids and flavonoids.  
 
 
 
Figure S1. Fractionation scheme. H. canadensis leaves were percolated in MeOH, subjected to 
liquid/liquid partitioning, and separated using four subsequent stages of chromatography, two 
rounds of flash chromatography over silica gel, followed by two rounds of preparatory scale 
HPLC. After each round of separation, each fraction was profiled using LC-MS and tested for 
antimicrobial activity, as shown in Figures 3 and 4 of the main text. 
 
 
 
 
 
 
 
Table S1. NMR spectroscopic data (500 MHz for 1H and 125 MHz for 13C, DMSO-d6) for H. 
canadensis flavonoids sideroxylin (1), 8-demethyl-sideroxylin (2), and 6-demethyl-sideroxylin 
(3). 
 
 
 
 
 
 
Figure S2. 1H NMR spectra (500 MHz, DMSO-d6) for H. canadensis flavonoids 1, 2, and 3. 
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